[Prodigiosin in the overall therapy of dysentery and in the prevention of intrahospital viral respiratory infection in children].
Prodigiozan was tested in complex therapy of children with acute dysentery. Comparison of clinical symptoms, specific immunogenesis and child sanation periods from Shigella in the child groups treated (80) and non-treated (74) with prodigiozan showed that prodigiozan lowered the rate of intrahospital acute respiratory virus infection, provided more favourable dysentery progression, more tensed specific immunity and the patient clearance from Shigella.
D000208:Acute Disease; D000917:Antibody Formation / Q000187:drug effects; D002675:Child, Preschool; D003428:Cross Infection / Q000276:immunology / Q000517:prevention & control*; D004405:Dysentery, Bacillary / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007223:Infant; D011353:Prodigiosin / Q000627:therapeutic use*; D012141:Respiratory Tract Infections / Q000276:immunology / Q000517:prevention & control*; D012763:Shigella flexneri / Q000302:isolation & purification; D012764:Shigella sonnei / Q000302:isolation & purification; D014777:Virus Diseases / Q000276:immunology / Q000517:prevention & control*
D011353:Prodigiosin
Prodigiozan v kompleksnoĭ terapii dizenterii i profilaktike vnutribol'nichnoĭ respiratornoĭ virusnoĭ infektsii u deteĭ